tiprankstipranks
Advertisement
Advertisement

OKUR Stock Latest News

OnKure Therapeutics to sell 26.713M shares at $4.15 in private placement
The FlyOnKure Therapeutics to sell 26.713M shares at $4.15 in private placement
1d ago
OKUR
OnKure Therapeutics: Positive View on OKI-219 Ahead of PIKture-1 Breast Cancer Data as Key Upside Catalyst
PremiumRatings
OnKure Therapeutics: Positive View on OKI-219 Ahead of PIKture-1 Breast Cancer Data as Key Upside Catalyst
12d ago
OKUR
OnKure Therapeutics price target lowered to $27 from $34 at H.C. Wainwright
PremiumThe Fly
OnKure Therapeutics price target lowered to $27 from $34 at H.C. Wainwright
12d ago
OKUR
OnKure Therapeutics reports Q4 EPS (99c), consensus ($1.15)
PremiumThe Fly
OnKure Therapeutics reports Q4 EPS (99c), consensus ($1.15)
16d ago
OKUR
OnKure Therapeutics Advances Clinical Programs and Expands Focus
PremiumCompany Announcements
OnKure Therapeutics Advances Clinical Programs and Expands Focus
5M ago
OKUR
Promising Prospects for OnKure Therapeutics: Buy Rating Backed by OKI-219 Developments and Strategic Expansion
PremiumRatingsPromising Prospects for OnKure Therapeutics: Buy Rating Backed by OKI-219 Developments and Strategic Expansion
5M ago
OKUR
Strategic Delay and Diversification: OnKure Therapeutics Positioned for Growth with Buy Rating
Premium
Ratings
Strategic Delay and Diversification: OnKure Therapeutics Positioned for Growth with Buy Rating
5M ago
OKUR
OnKure Therapeutics: Strategic Advancements and Promising Clinical Developments Drive Buy Rating
Premium
Ratings
OnKure Therapeutics: Strategic Advancements and Promising Clinical Developments Drive Buy Rating
5M ago
OKUR
OnKure Therapeutics files $200M mixed securities shelf
PremiumThe Fly
OnKure Therapeutics files $200M mixed securities shelf
5M ago
OKUR
OnKure Therapeutics Announces Sales Agreement with Leerink
PremiumCompany Announcements
OnKure Therapeutics Announces Sales Agreement with Leerink
5M ago
8K
OKUR
OnKure Therapeutics reports Q3 EPS ($1.09), consensus ($1.20)
PremiumThe Fly
OnKure Therapeutics reports Q3 EPS ($1.09), consensus ($1.20)
5M ago
OKUR
Promising Developments in OnKure Therapeutics’ PI3Kα Mutant Breast Cancer Treatment: Analyst Recommends Buy Rating
PremiumRatings
Promising Developments in OnKure Therapeutics’ PI3Kα Mutant Breast Cancer Treatment: Analyst Recommends Buy Rating
5M ago
OKUR
VTI ETF News, 10/9/2025
PremiumMarket NewsVTI ETF News, 10/9/2025
6M ago
LVO
VTI
VTI ETF News, 10/8/2025
Premium
Market News
VTI ETF News, 10/8/2025
6M ago
LVO
VTI
VTI ETF News, 10/7/2025
Premium
Market News
VTI ETF News, 10/7/2025
6M ago
VTI
BCAB
Buy Recommendation for OnKure Therapeutics Based on Strategic Development of PI3Kα Programs and Promising OKI-219 Trial Results
PremiumRatings
Buy Recommendation for OnKure Therapeutics Based on Strategic Development of PI3Kα Programs and Promising OKI-219 Trial Results
7M ago
OKUR
OnKure Therapeutics Advances Cancer Drug Development
PremiumCompany Announcements
OnKure Therapeutics Advances Cancer Drug Development
8M ago
OKUR
OnKure Therapeutics reports Q2 EPS ($1.14), consensus ($1.25)
PremiumThe Fly
OnKure Therapeutics reports Q2 EPS ($1.14), consensus ($1.25)
8M ago
OKUR
OnKure Therapeutics’ Strategic Delay and Confidence in PI3Ka Inhibitor Development Supports Buy Rating
PremiumRatings
OnKure Therapeutics’ Strategic Delay and Confidence in PI3Ka Inhibitor Development Supports Buy Rating
9M ago
OKUR
OnKure Therapeutics Updates on PI3Kα Inhibitor Progress
PremiumCompany AnnouncementsOnKure Therapeutics Updates on PI3Kα Inhibitor Progress
9M ago
8K
OKUR
Buy Rating for OnKure Therapeutics Driven by Promising Developments in Metastatic Breast Cancer Treatment and Strong Financial Position
Premium
Ratings
Buy Rating for OnKure Therapeutics Driven by Promising Developments in Metastatic Breast Cancer Treatment and Strong Financial Position
10M ago
OKUR
OnKure Elects Directors at Annual Stockholder Meeting
Premium
Company Announcements
OnKure Elects Directors at Annual Stockholder Meeting
10M ago
8K
OKUR

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >